Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

Abstract

Background Renal transplant recipients are at increased risk of premature cardiovascular disease. Although statins reduce cardiovascular risk in the general population, their efficacy and safety in renal transplant recipients have not been established. We investigated the effects of fluvastatin on cardiac and renal endpoints in this population.Methods We did a multicentre, randomised, double-blind, placebo-controlled trial in 2102 renal transplant recipients with total cholesterol 4.0-9.0 mmol/L. We randomly assigned patients fluvastatin (n=1050) or placebo (n=1052) and follow up was for 5-6 years. The primary endpoint was the occurrence of a major adverse cardiac event, defined as cardiac death, non-fatal myocardial infarction (MI), or coronary intervention procedure. Secondary endpoints were individual cardiac events, combined cardiac death or non-fatal MI, cerebrovascular events, non-cardiovascular death, all-cause mortality, and graft loss or doubling of serum creatinine. Analysis was by intention to treat.Findings After a mean follow-up of 5.1 years, fluvastatin lowered LDL cholesterol concentrations by 32%. Risk reduction with fluvastatin for the primary endpoint (risk ratio 0.83 [95% CI 0.64-1.06], p=0.139) was not significant, although there were fewer cardiac deaths or non-fatal MI (70 vs 104, 0.65 [0.48-0.88] p=0.005) in the fluvastatin group than in the placebo group. Coronary intervention procedures and other secondary endpoints did not differ significantly between groups.Interpretation Although cardiac deaths and non-fatal MI seemed to be reduced, fluvastatin did not generally reduce rates of coronary intervention procedures or mortality. Overall effects of fluvastatin were similar to those of statins in other populations.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)13638-0

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 925

Metadata

Authors
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., Maes, B., Ambuhl, P., Olsson, A. G., Hartmann, A., Solbu, D. O., & Pedersen, T. R.
Affiliations
  • Oslo University Hospital (NO)
  • Uppsala University Hospital (SE)
  • University of Glasgow (GB)
  • Sahlgrenska University Hospital (SE)
  • Charité – Universitätsmedizin Berlin (DE)
  • Toronto General Hospital (CA)
  • Universitair Ziekenhuis Leuven (BE)
  • Linköping University Hospital (SE)
  • Novartis (Norway) (NO)
Corresponding author
Holdaas, Hallvard
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-06
Volume
361
Issue
9374
Pages
2024-2031
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2156880046
Cited by
919
References
41
Citations by year
2026: 11 · 2025: 15 · 2024: 25 · 2023: 24 · 2022: 23 · 2021: 23 · 2020: 27 · 2019: 33 · 2018: 25 · 2017: 34 · 2016: 27 · 2015: 43 · 2014: 58 · 2013: 40 · 2012: 47
FWCI
61.85
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Novartis
  • Novartis Pharma
  • Merck Sharp and Dohme
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
fluvastatin, kidney transplant recipients, statins, cardiovascular risk, major adverse cardiac events, myocardial infarction, cardiovascular mortality, LDL cholesterol lowering, graft loss, all-cause mortality, coronary intervention
MeSH terms
Fluvastatin, Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Interactions, Fatty Acids, Monounsaturated, Female, Follow-Up Studies, Humans, Immunosuppressive Agents, Indoles, Cholesterol, LDL, Male, Middle Aged, Placebos, Risk Factors, Kidney Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(03)13638-0
The paper
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., Maes, B., Ambuhl, P., Olsson, A. G., Hartmann, A., Solbu, D. O., & Pedersen, T. R. (2003). Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(03)13638-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.